| Literature DB >> 25821811 |
Ahmed I Dakrory1, Sohair R Fahmy2, Amel M Soliman2, Ayman S Mohamed2, Sayed A M Amer1.
Abstract
Oxidative stress is a common mechanism contributing to the initiation and progression of hepatic damage. Hence there is a great demand for the development of agents with potent antioxidant effect. The aim of the present study is to evaluate the efficacy of Holothuria atra extract (HaE) as an antioxidant against 7,12-dimethylbenz[a]anthracene- (DMBA-) induced hepatorenal dysfunction. Experimental animals were divided into two main groups: protective and curative. Each group was then divided into five subgroups pre- or posttreated either with distilled water (DMBA subgroups) or with HaE (200 mg/kg body weight) for seven and fourteen days. Single oral administration of DMBA (15 mg/kg body weight) to Wistar rats resulted in a significant increase in the serum liver enzymes and kidney function's parameters. DMBA increased level of liver malondialdehyde (MDA), decreased levels of reduced glutathione (GSH), glutathione-S-transferase (GST), superoxide dismutase (SOD), and catalase (CAT) in the liver tissue, and induced liver histopathological alterations. Pre- or posttreatment with HaE orally for 14 days significantly reversed the hepatorenal alterations induced following DMBA administration. In conclusion, HaE exhibits good hepatoprotective, curative, and antioxidant potential against DMBA-induced hepatorenal dysfunction in rats that might be due to decreased free radical generation.Entities:
Mesh:
Substances:
Year: 2015 PMID: 25821811 PMCID: PMC4363541 DOI: 10.1155/2015/563652
Source DB: PubMed Journal: Biomed Res Int Impact factor: 3.411
Figure 1Schematic diagram shows the experimental design of treatment in the protective group.
Figure 2Schematic diagram shows the experimental design of treatment in the curative group.
Figure 3High-performance liquid chromatography analysis of Holothuria atra extract (HaE).
Figure 4Inhibition of DPPH of Holothuria atra extract (HaE).
Modulatory influence of Holothuria atra extract (HaE) on alanine (ALAT) and aspartate (ASAT) aminotransaminase activities of 7,12-dimethylbenz[a]anthracene (DMBA) treated rats.
| Treatment | Groups | ALAT | ASAT | |
|---|---|---|---|---|
| Pretreatment | Control | 134.25 ± 5.55ab | 175.05 ± 6.26a | |
| 7 days | DMBA | 159.50 ± 9.00cd | 217.35 ± 6.28de | |
| HaE | 151.85 ± 4.40bcd | 206.75 ± 5.36bcd | ||
| 14 days | DMBA | 177.75 ± 5.93e | 229.60 ± 3.38d | |
| HaE | 141.45 ± 5.12ab | 189.75 ± 3.48ab | ||
|
| ||||
| Posttreatment | Control | 133.85 ± 7.10a | 175.85 ± 6.25a | |
| 7 days | DMBA | 165.65 ± 4.49de | 209.60 ± 7.28cd | |
| HaE | 145.70 ± 2.75abc | 195.4 ± 10.73bc | ||
| 14 days | DMBA | 178.75 ± 5.33e | 229.75 ± 0.93d | |
| HaE | 138.70 ± 3.47ab | 194.60 ± 5.39bc | ||
Values are given as mean ± SEM for 6 rats in each group.
Each value not sharing a common letter superscript is significantly different (P < 0.05).
Modulatory influence of Holothuria atra extract (HaE) on gamma glutamyl transferase (GGT) activity and total protein content of 7,12-dimethylbenz[a]anthracene (DMBA) treated rats.
| Treatment | Groups | GGT | Total protein | |
|---|---|---|---|---|
| Pretreatment | Control | 2.54 ± 0.67a | 17.54 ± 0.45d | |
| 7 days | DMBA | 5.21 ± 0.81de | 12.59 ± 0.74bc | |
| HaE | 2.08 ± 0.43abc | 12.12 ± 0.19b | ||
| 14 days | DMBA | 60.16 ± 17.90e | 14.616 ± 0.59c | |
| HaE | 16.90 ± 6.52ab | 9.96 ± 0.36a | ||
|
| ||||
| Posttreatment | Control | 2.48 ± 0.63a | 16.86 ± 0.57d | |
| 7 days | DMBA | 7.64 ± 2.68de | 12.51 ± 1.01bc | |
| HaE | 3.24 ± 0.29abc | 12.79 ± 0.28bc | ||
| 14 days | DMBA | 67.39 ± 21.26e | 12.85 ± 0.18bc | |
| HaE | 44.60 ± 15.53ab | 9.42 ± 1.40a | ||
Values are given as mean ± SEM for 6 rats in each group.
Each value not sharing a common letter superscript is significantly different (P < 0.05).
Modulatory influence of Holothuria atra extract (HaE) on some kidney function parameters of 7,12-dimethylbenz[a]anthracene (DMBA) treated rats.
| Treatment | Groups | Creatinine | Uric acid | Urea | |
|---|---|---|---|---|---|
| Pretreatment | Control | 0.70 ± 0.02a | 1.50 ± 0.14a | 4.43 ± 0.43ab | |
| 7 days | DMBA | 1.15 ± 0.06b | 2.15 ± 0.23cd | 5.78 ± 0.40cd | |
| HaE | 0.98 ± 0.01b | 1.67 ± 0.14abc | 4.61 ± 0.30ab | ||
| 14 days | DMBA | 2.17 ± 0.15d | 2.69 ± 0.18e | 5.54 ± 0.14cd | |
| HaE | 1.15 ± 0.05b | 1.30 ± 0.17a | 4.88 ± 0.22b | ||
|
| |||||
| Posttreatment | Control | 0.73 ± 0.02a | 1.51 ± 0.15a | 4.39 ± 0.43ab | |
| 7 days | DMBA | 1.20 ± 0.06b | 2.07 ± 0.18bcd | 5.06 ± 0.09cd | |
| HaE | 0.97 ± 0.01b | 1.42 ± 0.14a | 5.06 ± 0.09cd | ||
| 14 days | DMBA | 1.85 ± 0.12c | 2.45 ± 0.09de | 6.15 ± 0.05d | |
| HaE | 1.16 ± 0.05b | 1.59 ± 0.12ab | 4.49 ± 0.45ab | ||
Values are given as mean ± SEM for 6 rats in each group.
Each value not sharing a common letter superscript is significantly different (P < 0.05).
Modulatory influence of Holothuria atra extract (HaE) on liver, malondialdehyde (MDA), and reduced glutathione (GSH) levels of 7,12-dimethylbenz[a]anthracene (DMBA) treated rats.
| Treatment | Groups | MDA | GSH | |
|---|---|---|---|---|
| Pretreatment | Control | 3.24 ± 0.04a | 3.90 ± 0.54c | |
| 7 days | DMBA | 3.44 ± 0.07ab | 1.43 ± 0.31a | |
| HaE | 3.46 ± 0.04ab | 1.98 ± 0.30ab | ||
| 14 days | DMBA | 4.79 ± 0.53cd | 1.35 ± 0.10a | |
| HaE | 3.50 ± 0.12ab | 1.66 ± 0.27b | ||
|
| ||||
| Posttreatment | Control | 3.21 ± 0.04a | 3.81 ± 0.57c | |
| 7 days | DMBA | 4.12 ± 0.36bc | 2.90 ± 0.16d | |
| HaE | 4.03 ± 0.13b | 1.58 ± 0.05a | ||
| 14 days | DMBA | 5.05 ± 0.25d | 1.39 ± 0.12a | |
| HaE | 3.95 ± 0.12ab | 2.14 ± 0.09b | ||
Values are given as mean ± SEM for 6 rats in each group.
Each value not sharing a common letter superscript is significantly different (P < 0.05).
Modulatory influence of Holothuria atra extract (HaE) on some liver antioxidant enzymes activities of 7,12-dimethylbenz[a]anthracene (DMBA) treated rats.
| Treatment | Groups | GST | SOD | CAT | |
|---|---|---|---|---|---|
| Pretreatment | Control | 2.70 ± 0.49a | 264.08 ± 28.23d | 686.40 ± 73.64d | |
| 7 days | DMBA | 1.51 ± 0.18b | 201.53 ± 13.72b | 473.6 ± 55.50ab | |
| HaE | 1.45 ± 0.08b | 183.21 ± 9.71ab | 448.00 ± 14.96ab | ||
| 14 days | DMBA | 1.13 ± 0.16b | 168.32 ± 2.48ab | 362.40 ± 41.83a | |
| HaE | 2.18 ± 0.24a | 214.53 ± 6.87c | 560.00 ± 65.72bc | ||
|
| |||||
| Posttreatment | Control | 2.68 ± 0.49a | 268.14 ± 28.84d | 683.40 ± 73.68d | |
| 7 days | DMBA | 1.63 ± 0.24b | 166.39 ± 12.81ab | 472.00 ± 32.00ab | |
| HaE | 1.54 ± 0.10b | 164.14 ± 11.81ab | 552.00 ± 38.78bc | ||
| 14 days | DMBA | 1.20 ± 0.13b | 146.14 ± 7.96a | 440.00 ± 17.88ab | |
| HaE | 2.21 ± 0.10a | 220.10 ± 2.87c | 584.00 ± 29.93c | ||
Values are given as mean ± SEM for 6 rats in each group.
Each value not sharing a common letter superscript is significantly different (P < 0.05).
Figure 5Hematoxylin and eosin stained liver sections from (a) control rats; ((b) and (c)) DMBA intoxicated rats in pre- and posttreatment groups for 7 days; ((d) and (e)) DMBA intoxicated rats in pre- and posttreatment groups for 14 days; (f) 7-day pretreatment rats with HaE; (g) 7-day posttreatment rats with HaE; (h) 14-day pretreatment rats with HaE; (i) 14-day posttreatment rats with HaE (H&E × 400).